Prothena | PRTA - Loan Capital


Prothena reported $0 in Loan Capital for its fiscal quarter ending in December of 2024.





Loan Capital Change Date
Acadia Pharmaceuticals USD 0 0 Mar/2025
Agios Pharmaceuticals USD 1.06M 0 Sep/2022
Akebia Therapeutics USD 48.25M 609K Dec/2025
ALKERMES USD 285.82M 639K Sep/2024
Alnylam Pharmaceuticals USD 2.48B 1.44B Dec/2025
Amgen USD 50B 2.43B Dec/2025
Biogen USD 6.29B 1.4M Sep/2025
BioMarin Pharmaceutical USD 597.18M 513K Dec/2025
Immunic USD 0 0 Jun/2024
Incyte USD 30.2M 5.17M Dec/2025
Ionis Pharmaceuticals USD 1.9B 1.87B Dec/2025
MacroGenics USD 70.26M 4K Sep/2025
Nektar Therapeutics USD 107.51M 10.35M Jun/2024
Neurocrine Biosciences USD 169.5M 500K Mar/2023
Prothena USD 0 0 Dec/2024
Regeneron Pharmaceuticals USD 2.71B 720.4M Dec/2025
Ultragenyx Pharmaceutical USD 763.74M 19.02M Sep/2025
Vertex Pharmaceuticals USD 111.4M 1.4M Mar/2025
Xoma USD 94.38M 7.82M Sep/2025